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Abstract
This systematic review summarizes the existing data on headache and pregnancy with a scope on clinical headache
phenotypes, treatment of headaches in pregnancy and effects of headache medications on the child during
pregnancy and breastfeeding, headache related complications, and diagnostics of headache in pregnancy.
Headache during pregnancy can be both primary and secondary, and in the last case can be a symptom of a
life-threatening condition. The most common secondary headaches are stroke, cerebral venous thrombosis,
subarachnoid hemorrhage, pituitary tumor, choriocarcinoma, eclampsia, preeclampsia, idiopathic intracranial
hypertension, and reversible cerebral vasoconstriction syndrome. Migraine is a risk factor for pregnancy complications,
particularly vascular events. Data regarding other primary headache conditions are still scarce. Early diagnostics of the
disease manifested by headache is important for mother and fetus life. It is especially important to identify “red flag
symptoms” suggesting that headache is a symptom of a serious disease. In order to exclude a secondary headache
additional studies can be necessary: electroencephalography, ultrasound of the vessels of the head and neck, brain MRI
and MR angiography with contrast ophthalmoscopy and lumbar puncture. During pregnancy and breastfeeding the
preferred therapeutic strategy for the treatment of primary headaches should always be a non-pharmacological one.
Treatment should not be postponed as an undermanaged headache can lead to stress, sleep deprivation, depression
and poor nutritional intake that in turn can have negative consequences for both mother and baby. Therefore, if
non-pharmacological interventions seem inadequate, a well-considered choice should be made concerning the
use of medication, taking into account all the benefits and possible risks.
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Introduction
Headache is the most frequent referral for neurologic
consultation in the outpatient setting. The last release of
data at 2013 from the Global Burden of Disease (GBD) -
described now as “the most comprehensive worldwide
observational epidemiological study to date” [1] - estab-
lished headache disorders collectively as the seventh
highest cause of years lived with disability (ylds) [2].
In front of a patient complaining about headache, the
first purpose is to distinguish a primary headache (when
pain is the disease) from a secondary headache (when
pain is a symptom of another disease). More strictly, this
is the main concern with a pregnant woman suffering
from this symptom. Three scenarios are possible [3, 4]:
1. She suffers from a primary headache and now she
presents with her usual headache;
2. She does not suffer from a primary headache and
she presents with her first severe headache during
pregnancy;
3. She suffers from a primary headache, but now pain is
different in quality, intensity or associated symptoms.
In the second and third scenarios, headache must be
considered as a symptom of an underlying disease until an
appropriate diagnostic evaluation has been performed.
This systematic review is a summary of existing data
on headache and pregnancy with a focus on clinical
headache phenotypes, treatment of headaches in pregnancy
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and effects of headache medication on the child during
pregnancy and breastfeeding, headache-related complica-
tions, and diagnostics of headache in pregnancy.
Methods of review
Two independent reviewers conducted an independent
search on pubmed using the search terms “pregnancy”
and “headache” OR “migraine”, each combined with
“complications” OR “treatment” OR “management”.
This search was carried out on June 15th, 2017. We
included articles from the past 20 years. The initial
screening was conducted based on eligibility of titles
and abstracts. Original works, randomized, placebo-
or comparator-controlled trials, published in full, were
primarily selected for the review. Other references
quoted include: systematic reviews, open label studies,
retrospective studies, population-based studies, guide-
lines, manufacturers product monographs and letters
to the editor. Discrepancies between reviewers were
resolved by discussion.
Clinical headache phenotypes and observational
studies in pregnancy
Primary headaches
In most cases headache is a primary disorder, including
migraine and tension-type headache (TTH) as the more
frequent conditions that affect women asking medical
consultation. Several observational studies have been
conducted to evaluate the course of primary headaches
during pregnancy (Table 1). During pregnancy, primary
headaches also showed a tendency to change in pattern
from migraine without aura (MO) to migraine with aura
(MA) and vice versa or from MO to TTH and vice
versa: in an Italian study 9% of TTH patients developed
MO during gestation, while 10% did the opposite [5]. Up-
to-date, TTH is not correlated with any adverse pregnancy
outcomes, even if sample size of the available studies are
too small to achieve definitive conclusions [4].
Migraine
On the wake of the first pioneering articles [6, 7], following
retrospective and prospective studies dealing with migraine
and pregnancy published in the last twenty years show
similar results. About one half to three fourths of female
migraineurs experience a marked improvement in migraine
during pregnancy with a significant reduction in frequency
and intensity of their attacks, if not a complete resolution
(Table 1) [8–18]. The remaining attacks show a progressive
reduction in the mean pain intensity and duration as
pregnancy proceeds [13, 17]. As a consequence, the 1-year
headache prevalence of migraine and non-migrainous
headache is lower among nulliparous pregnant women
than in non-pregnant women [19]. Maggioni et al. Re-
ported an absolute improvement during the first trimester,
with a further reduction during the second and third ones
[5], a data that has been confirmed by more recent studies
[9, 13]. Differently, the Head-HUNT study found a marked
reduction in headache burden only in the third trimester
[19]. About 50% of the pluripara mothers present a persist-
ent worsening of their headache with following gestations
[5]. This is in line with the evidence that multiparous
subjects more likely experience worsening of headache [9].
Other studies showed no significant differences between
primi- and multiparous pregnant women as regards the
course of headaches during gestation among migraineurs
[17, 19], neither confirming the trend of further improve-
ment after the first trimester [10]. A large Italian study
found that the percentage of remissions during pregnancy
was significantly higher in the subgroup of patients whose
migraine started at menarche and in those suffering from
menstrual migraine [8], even if this last data has not been
confirmed by following studies [10, 13, 14].
Migraine without aura (MO) can start during preg-
nancy in 1 up to 10% of pregnant women [5, 15–17, 20],
with some retrospective data rising up to 16.7% [13]; this
is classically considered a first trimester phenomenon
[5–7, 20]. In other cases, migraine can worsen during
pregnancy, especially in the first trimester: this is reported
in 8% of cases (Table 1) [5, 8–16]. Except for a few works
concerning headache frequency [5, 13, 15], most articles
analyse headache modifications during pregnancy without
distinguishing between frequency and intensity of the
attacks. A mean of 25% of MO patients will continue to
have attacks during pregnancy, with hyperemesis, patho-
logical pregnancy course and pre-gestation menstrual-
related migraine being linked with this lack of improvement
[13, 21]. Up-to-date, scientific literature lacks of large and
rigorous studies aimed at understanding factors possibly
associated with the absence of a clinical improvement
during pregnancy [22, 23].
The relationship between estrogens fluctuations and
MA has been the focus of fewer studies. MA starts or
worsens during pregnancy more frequently than MO
does: onset during gestation is reported in 10.7 up to
14% of cases [5, 11], worsening covers 8.4% of MA women
(Table 1), with “no change” in pain pattern representing
the most frequent evolution during gestation. Nearly half
patients with MA will continue to have attacks [11]. This
trend to recede in a lower number of cases than MO has
been transversely confirmed [5, 13, 14], with rare excep-
tions [16]. It could be due to increased endothelial reactiv-
ity in MA patients compared with MO ones [21]. MA can
develop new aura symptoms during gestation [24, 25], as
pregnancy may trigger attacks of aura without headache
as well [26]. In less frequent cases, hemiplegic migraine
makes the differential diagnosis very difficult, especially in
the third trimester [27, 28]. Therefore, we can easily
understand why transient neurologic symptoms during
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pregnancy are more common among pregnant women
with migrainous headache than in those without headache
or with non-migrainous headache [15].
Postpartum headache occurs in about 30–40% of all
women, not only migraineurs [6, 9, 13]. Most of the
attacks develop during the first week after delivery, with
apparent sparing of the day of birth. During puerperium
mean headache intensity, pain duration and analgesic
therapies increase, as confirmed by a large prospective
trial [17]. On the other side, the MIGRA study showed a
decline in attacks frequency starting five weeks after
delivery [17]. None of the migraineurs experiencing a
complete pain remission during the first or the second
trimester should experience a recurrence of migraine
attacks before delivery [13], even if a study reported an
increase in headache burden already in the four weeks
before birth in multiparous women, defining a U-shaped
curve to describe migraine evolution during pregnancy
[9]. A large multicentre study set at 3.7% the amount of
women experiencing headache within 72 h after delivery,
identifying headache during pregnancy and regional
anaesthesia injections as risk factors [28]. Migraine usu-
ally returns quickly after delivery, probably triggered by
the abrupt fall in the level of estrogens, by a postpartum
depression or because of the new parental role and all
that it implies (sleep deprivation, anxiety, worry and psy-
chological adaptation). Pre-pregnancy headache pattern
restores within 1 month from delivery in 55% of patients
and only breast-feeding and age > 30 years have been
reported to retard headache recurrence [13]. Migraine
recurred within the first post-partum month in 100% of
women who bottle-fed and in only 43.2% of those who
breastfed [13]. However, other studies found no significant
association between headache improvement from the sec-
ond trimester to the postpartum and breastfeeding [10, 17].
At present only one study dealt with the headache attacks
during the course of in vitro fertilization and embryo-
transfer treatments [29]. The prevalence of headache
attacks is higher at the first stage of the procedure
(with gnrh analogue administration) and at the end of
the treatment protocol in cases there is no conception,
in both situations because of a decline in blood levels
of estrogens.
Tension-type headache
TTH represents 26% of headaches in pregnancy [30].
TTH would be expected to improve during gestation as
female hormones modulate serotonin and endorphins,
which are involved in TTH pathophysiology [4]. Actu-
ally, 17.9% of TTH patients reported no change in the
headache burden during pregnancy (Table 1), with wors-
ening in 5% of cases and improvement in a quarter of
women [3, 30]. A study found significantly higher remis-
sion and improvement rates than in MO (Table 1) [5].
Whatever if women with TTH showed a great or a modest
improvement, this is usually reported as marked as for the
migraineurs [10, 16]. On the contrary, TTH rarely worsens
during gestation [16] and, according to some Authors, it
never does [5].
Cluster headache
Cluster headache (CH) is a relatively rare primary head-
ache, severe in intensity, stabbing in quality, highly debili-
tating, associated with autonomic symptoms and affecting
men more frequently than women. Scientific literature
lacks of large prospective studies about the effect of preg-
nancy on CH, as it is seen in less than 0.3% of pregnancies
[30]. Despite the rare cases in which the first attacks occur
during the first pregnancy, almost a quarter of pregnant
women report that an expected cluster period does not
develop during gestation while it may start soon after
delivery [31]. Otherwise, CH attacks do not change in
intensity and frequency in the majority of cases. As a con-
sequence, women who have their first attack before their
first gestation usually have fewer children than those who
already were mother at the time of clinical onset; this is
probably due to the prospective of the treatment limita-
tions in case of CH during pregnancy [31].
Secondary headaches
Pregnancy is a risk factor for a secondary headache
disorder. Hypercoagulability, hormonal changes and
anaesthesia for labour are just some of the multiple
factors contributing to the high incidence of secondary
headaches during pregnancy.
A recent study by Robbins et al. Found 35% of secondary
headaches among 140 pregnant women presenting with
acute headache: hypertensive disorders of pregnancy
covered 51% of these cases (about 18% of total), with pre-
eclampsiaasthemajorcause, followedbyreversibleposter-
ior leukoencephalopathy syndrome (PRES, eclampsia),
reversiblecerebralvasoconstrictionsyndrome(RCVS)and
acute arterial hypertension [32]. These data place between
two previous studies that reported percentages of second-
aryheadaches ranging from14.3% to52.6% [16, 33]. In par-
ticular, among patients with a primary headache history,
longerattackdurationisthemostcommonfeaturesuggest-
ing a secondary headache, reaching the statistical signifi-
cance[32]or justapproachingit[33].
The authors show how lack of headache history, elevated
blood pressure and abnormalities at neurologic examin-
ation are the main red flags for a secondary origin of an
acute headache during pregnancy [32]. In the second tri-
mester, a new onset of headache may signal the presence of
a pseudotumor cerebri [34], while in case of a severe pos-
tural headache a spontaneous intracranial hypotension
must be ruled out [35]. In front of the well-known red flags
(Table 2) brain MRI or CT scan are often required [30, 36].
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Use of contrast agents such as gadolinium is not recom-
mended, given the lack of data regarding safety to the fetus
and its ability to cross the placenta and remain in the amni-
otic fluid [30].
Iodinated contrast should be avoided as well as it may
suppress fetal thyroid function [37].
Recently the European Headache Federation (EHF)
published a consensus statement on technical investiga-
tion for primary headache disorders [38].
Secondary headache features may not differ from those
of primary headaches; furthermore, migraine is as an
independent risk factor for the development of secondary
headaches (e.g., the risk of gestational hypertension in-
creased by 1.42-fold with an OR of 2.3 (CI 2.1–2.5) [39],
so that recognizing these conditions in pregnant women
may be a true diagnostic challenge.
Cerebral venous thrombosis (CVT), pre-eclampsia,
haemorrhagic or ischemic stroke, subarachnoid haemor-
rhage (SAH), RCVS, PRES, idiopathic intracranial hyper-
tension (IIH) or pituitary apoplexy must be ruled out as
soon as possible (Table 3) [3, 37].
Cerebral venous thrombosis
Headache caused by CVT has no specific characteristics:
it is most often diffuse, progressive and severe, but can
be unilateral and sudden (even thunderclap), or mild,
and sometimes is migraine-like [40]. Headache is present
in 80–90% of cases of CVT and it is often associated with
focal signs (neurological deficits or seizures) and/or signs
of intracranial hypertension (nausea and papilledema),
subacute encephalopathy or cavernous sinus syndrome,
carrying a mortality rate of up to 30% [30].
Pre-eclampsia and eclampsia
Pre-eclampsia occurs in 5% of pregnancies [30]: a pro-
gressive bilateral (temporal, frontal, occipital or diffuse)
pulsating headache in a woman who is pregnant or in
the puerperium (up to 4 weeks postpartum), often aggra-
vated by physical activity, failing to respond to the over-the-
counter remedies, may be the herald symptom of this
condition, which can associate with visual changes similar
to the typical visual aura. It must resolve within a week
after blood pressure adjustment [4, 41]. According to
the International Classification of Headache Disorders
(ICHD-3beta) headache should have at least two of the
following three characteristics: a) bilateral location, b) pul-
sating quality, and c) aggravated by physical activity [42].
Ischaemic stroke
Headache accompanies ischaemic stroke especially within
the posterior circulation, in up to one-third of cases and is
usually overshadowed by focal signs and/or alterations of
consciousness, which in most cases allows easy differenti-
ation from the primary headaches. The risk of ischaemic
stroke in migraineurs was evaluated using the United States
(US) Nationwide Inpatient Sample from the Healthcare
Cost and Utilization Project of the Agency for Healthcare
Research and Quality and found to be elevated [39].
Headache has a self-limited course, and is very rarely the
presenting or a prominent feature of ischaemic stroke [43].
It is usually of moderate intensity, and has no specific char-
acteristics. It can be bilateral or unilateral ipsilateral to the
stroke. Rarely, an acute ischaemic stroke can present with
an isolated sudden (even thunderclap) headache [44].
Table 2 Red Flags for headache in pregnancy
1. Headache that peaks in severity in less than five minutes
2. New headache type versus a worsening of a previous headache
3. Change in previously stable headache pattern
4. Headache that changes with posture (e.g. Standing up)
5. Headache awakening the pregnant
6. Headache precipitated by physical activity or Valsalva manoeuvre
(e.g. Coughing, laughing, straining)
7. Thrombophilia
8. Neurological symptoms or signs
9. Trauma
10. Fever
11. Seizures
12. History of malignancy
13. History of HIV or active infections
14. History of pituitary disorders
15. Elevated blood pressure
16. Recent travel at risk of infective disease
Modified from Mitsikostas et al. 2015 [38] (European Headache Federation
consensus on technical investigation for primary headache disorders)
Table 3 Main causes of secondary headache in pregnant women
Secondary headaches during pregnancy
Arterial dissection Intracranial hypotension
Arteriovenous malformation Ischemic stroke
Brain tumors Meningitis/encephalitis
Cerebral venous thrombosis (CVT) Pituitary adenoma
Choriocarcinoma Pituitary apoplexy
Cranial neuralgias Pituitary meningioma
Dehydration Reversible posterior
leukoencephalopathy
syndrome (PRES)
Eclampsia and pre-eclampsia Reversible vasoconstriction
syndrome (RCVS)
Head trauma Sinusitis
Idiopathic intracranial hypertension (IIH) Subarachnoid haemorrhage
(SAH)
Intracranial haemorrhage (ICH) Vasculitis
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The diagnosis of headache and its causal link with
ischaemic stroke is easy because the headache presents
both acutely and with neurological signs and because it
often remits rapidly.
Subarachnoid haemorrhage
In SAH headache is usually the prominent symptom.
The pain is typically severe and sudden, peaking in seconds
(thunderclap headache) or minutes, often followed by
vomiting and loss of consciousness [45]. SAH is a serious
condition with mortality rate of 40–50% and with 10–20%
of patients dying before arriving at hospital. The abrupt on-
set is the key feature and can help to distinguish from pri-
mary headaches with thunderclap features (e.g., associated
with exercise or sexual activity). SAH presents a 20-fold in-
creased risk in the puerperium and it gives a thunderclap
headache [30].
Arterial dissection
Arterial dissection is a rare complication of pregnancy
and puerperium. There have been reports of cervical
carotid, vertebral and intracranial artery dissection in
association with preeclampsia [46]. Headache is the most
frequent inaugural symptom, described as severe, unilateral
(ipsilateral to the dissected vessel), with a sudden (even
thunderclap) onset. Pain is persistent for days and can
remain isolated or be a warning symptom preceding
ischaemic infarcts.
Reversible cerebral vasoconstriction syndrome
Headache caused by RCVS syndrome is severe and dif-
fuse and typically of the thunderclap type, recurring over
1–2 weeks, often triggered by sexual activity, exertion,
Valsalva manoeuvres and/or emotion [47]. Headache is
often the only symptom of RCVS, but the condition can
be associated with fluctuating focal neurological deficits
and sometimes seizures.
RCVS is commonly associated with the post-partum
period, usually within a week after delivery: its severe
thunderclap headache usually relapses within a few days,
resolving by approximately twelve weeks after clinical
onset [21, 37]. The typical differential diagnosis is cere-
bral vasculitis, which needs to be ruled out due to the
course of the disease and different treatment options.
Posterior reversible encephalopathy syndrome
PRES is a neuro-radiological clinical entity characterized
by insidious onset of headache, impaired consciousness,
visual changes or blindness, seizures, nausea, and vomiting,
and focal neurological signs. In nearly 2/3 of patients with
PRES, headache is the most common symptom and is
usually described as occipital and bilateral and dull in
nature [48]. Symptoms develop without prodrome, and
progress over 12–48 h.
PRES is often associated with hypertensive encephal-
opathy, preeclampsia, eclampsia, RCVS, renal failure,
immunosuppressive therapy or chemotherapy. PRES is
more common in women and the development of this
condition after delivery is unusual. The condition is usually
reversible when early diagnosis is established and appropri-
ate treatment is started without delay; symptoms generally
resolve within a period of days or weeks while recovery of
the MRI abnormalities takes longer [49].
Idiopathic intracranial hypertension
Usually during the first trimester, obese women can suffer
from a progressive, daily headache, aggravated by Valsalva
and position change, associated with papilledema and se-
vere visual deficits, together with tinnitus or sixth-nerve
palsies, defining the clinical pattern of IIH [30, 37, 50].
The headache is frequently described as frontal, retro-
orbital, ‘pressure like’ or explosive; migraine-like headache
may also occur.
Pituitary apoplexy
Pituitary apoplexy is a rare cause of sudden and severe
headache during pregnancy [51]. The sudden rise of a
severe headache, with nausea, vomiting, ophtalmoplegia,
altered consciousness and accompanied from onset or
later by visual symptoms and/or hypopituitarism must
raise the clinical suspicion of a pituitary apoplexy [4, 50].
The rare clinical syndrome of pituitary apoplexy is an
acute, life-threatening condition. It is important to dis-
tinguish from the other causes of thunderclap headache
[52]. Most cases occur as the first presentation of rapid
enlargement of non-functioning pituitary macroadeno-
mas as a result of haemorrhage and/or infarction.
Treatment of headaches in pregnancy and
breastfeeding women
During pregnancy, inadvertent exposure to teratogenic
agents can lead to irreversible fetal malformations [53, 54].
Unfortunately, most patients are not aware of possible
teratogenic risks of used medications and their safety pro-
files during pregnancy [55].
During pregnancy and breastfeeding the preferred thera-
peutic strategy should always be a non-pharmacological
one. Nevertheless, an undermanaged headache can lead to
stress, sleep deprivation, depression and poor nutritional in-
take which in turn can have negative consequences for
mother and baby. Therefore, if non-pharmacological inter-
ventions seem inadequate, a well-considered choice should
be made concerning the use of medication, taking into
account all the benefits and possible risks (Tables 4 and 5).
A basic rule should be to aim for the lowest effective dose
and the shortest duration of treatment.
Medication is considered safe during breastfeeding if the
relative infant dose is <10% [36, 56]. The risk of adverse
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events could be minimized by taking medication dir-
ectly after breastfeeding and discarding all milk for at
least 4 h [18].
Non-pharmacological treatment
Triggers like sleep deprivation, skipping meals and
emotional stress should be avoided. A balanced life-
style with attention for physical activity and regular
eating and sleeping habits is recommended [37, 57–62].
Acupuncture and behavioral therapies like biofeeback
and yoga can be helpfull [37, 58, 62]. In particular
for women with CH screening for sleep apnea is
usefull, since prevelance seems higher in cluster pa-
tients and in pregnancy [63]. Treatment with a den-
tal device or continuous positive airway pressure can
be proposed [57].
Table 5 Summarizing table on treatment of headache in breatsfeeding women
Medication Adverse effects Comments
Paracetamol – Preferred acute treatment
Nsaids (Non-selective):
Ibuprofen, naproxen,
indomethacin
Aggravation of jaundice Ibuprofen preferred
Triptans – - sumatriptan: no need to ‘pump and dump’
- less evidence on the other triptans: avoid nursing for 24 h after
use of triptan as extra safety measurement
Aspirin (ASA) Reye’s syndrome Not recommended
Caffeine – Moderate dosage
High flow oxygen – Preferred acute treatment in CH
Lidocaine – - second line acute treatment in CH
- intranasal formulation preferred
Corticosteroids:
prednisone, prednisolone
Prolonged high-dosed therapy: infant growth and
development can be affected
Intravenously: delay breastfeeding for 2-8 h
Weak opioids: tramadol,
codeine
Sedation and respiratory depression in the infant Not considered first line treatment in primary headaches
Ergots/Ergots Alkaloids - vomiting, diarrhea, convulsions
- decrease of prolactine in the mother
Avoid in any trimester
Β-blockers: metoprolol,
propranolol
- hypotension, bradycardia
- weakness
- metoprolol preferred
- avoid in children with astma
ACE-I, ARB Impact on kidney development Probably compatible (limited data)
Verapamil – First line CH profylaxis
TCA – No reported AE
Venlafaxine – No reported AE
Duloxetine – No reported AE
Valproate Interfere with liver and platelet function Avoid in women of child-bearing age
Topiramate - sedation, irritability
- poor suckling, diarrhea
–
Gabapentin – No reported AE
Lamotrigine – No reported AE
Magnesium, Riboflavine – No reported AE
Flunarizine – Not recommended: no data available
Lithium Renal toxicity Not recommended, but can be considered in uncontrolled CH,
refractory to Verapamil
Botox – No reported AE when injected correctly
Nerve blocks – No reported AE when injected correctly
Adverse effects are the known proven side effects. Concerns cover issues that are presumed based on limited data but for which the causal relationship is
not clear
TR1, first trimester; TR2, second trimester; TR3, third trimestes; AE, adverse effects; ADHD, attention-deficit/hyperactivity disorder; CM, congenital malformation;
CH: cluster headache, TCA, tricyclic antidepressants; ACE-I, ACE-inhibitor; ARB, angiotensin-receptor blocker; I.V., intravenously
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Symptomatic treatment
Paracetamol/acetaminophen
Paracetamol is considered the safest option to treat acute
pain during pregnancy and breastfeeding [37, 50, 54, 59–62,
64, 65]. Despite this historical reputation, new data suggest-
ing a possible relationship between prenatal exposure to
paracetamol and an increased risk of asthma and attention-
deficit/hyperactivity disorder (ADHD) in the child raise
some concern [37, 60, 62]. Patients should be educated
about the difference between paracetamol and combinated
drugs containing paracetamol and other substances, like
codeine or caffeine.
Aspirin
The use of acetylsalicylic acid (ASA) in low doses (<
100 mg/day) does not seem to induce any associated mater-
nal or neonatal complications. However, higher doses
should be avoided as well as its use in the third trimester,
since there might be a link with premature closure of the
ductus arteriosus and oligohydramnios [20, 50, 53, 54, 60].
Due to its effect on platelet function, ASA can also increase
the risk of neonatal bleeding [18].
Breastfeeding women should be discouraged to use ASA
due to a potential toxicity. It is associated with Reye’s syn-
drome. A potential adverse effect on platelet function in
the infant is suspected, but remains unclear [37, 59, 61, 64].
Caffeine
In animal studies a teratogenic effect of high-dosed caffeine
was demonstrated. On the other hand, caffeine-containing
beverages are consumed very commonly during pregnancy,
without any reported adverse effect. In general the use of
caffeine in low doses is assumed to be safe. Moderate-to-
high daily doses are more controversial since they might be
associated with miscarriage, low birth weight and preterm
delivery [60, 62, 66]. Combined preparations containing
paracetamol, aspirin and caffeine should be avoided [50].
Moderate intake of caffeine seems safe for mother and
child when breastfeeding [64].
Non-steroidal anti-inflammatory drugs
Attention should be paid to the timing of the pregnancy
and the type of non-steroidal anti-inflammatory drugs
(nsaids) used. Non-selective COX-inhibitors like ibupro-
fen, naproxen and diclofenac can be a relative safe choice
in the second trimester. Nsaids are not recommended in
the third trimester since there is an increased risk of com-
plications like premature closure of the ductus arteriosus,
impaired renal function, cerebral palsy and neonatal intra-
ventricular haemorrhage [50, 61, 62, 66]. More recent data
suggest to avoid nsaids during the first trimester as well.
An increased risk of miscarriage is suspected when used
close to conception based on available reports and seems
plausible regarding the pharmacological properties of this
drug. Different studies covering over 20.000 pregnancies
reported on the association between congenital malforma-
tion and prenatal nsaids exposure in the first trimester.
Some population-based studies confirm the association,
but others do not [37, 60, 61]. Selective COX2-inhibitors
are contraindicated in pregnancy based on the few pre-
natal data available [60].
Naproxen, indomethacin and ibuprofen are compatible
with breastfeeding, prefering ibuprofen because of its
short elimination half-life and low excretion in human
milk. In newborns with jaundice nsaids exposure can
exacerbate the condition [37, 60, 61, 64].
Triptans
Considerable data is available on the use of sumatriptan
in pregnancy. A few large pregnancy registries covering
more than 3000 pregnancies, retrospectively analyse the
use of other triptans, in particular rizatriptan, zolmitriptan
and eletriptan [37, 56]. Due to its small molecular weight,
sumatriptan can pass through the placenta [67]. However,
the transfer is slow and passive, so that only about 15% of
maternal dose reach the fetus after 4 h [68]. Ephross et al.
Reported the last data from the sumatriptan and naratrip-
tan pregnancy registries [69]. Until 2012, the registry
included 680 exposed women, giving birth to 689 fetuses.
90.9% of them were exposed to sumatriptan. The overall
risk of major birth defects under sumatriptan exposure was
4.2%. The most common birth defects were ventricular sep-
tal defect (n = 4), pyloric stenosis (n = 3) and chromosomal
abnormalities (n = 5). The authors concluded that suma-
triptan does not lead to teratogenity, as risk rates for major
birth defects were similar to general population (3–5%).
Only one major birth defect, i.e. Ventricular septal defect,
occurred under naratriptan exposure during first trimester
in a fetus who was also exposed to sumatriptan. The
number of newborns exposed to naratriptan was too
low to allow accurate interpretation [69]. In the riza-
triptan registry 4 major birth malformations occurred
in 56 pregnancies (7.1%). Also in this case data are cur-
rently too scarce to draw any conclusion [56, 70]. Ob-
servational studies conducted in Denmark, Sweden and
Norway reported no increased risk for fetal malformations
under triptan use [67, 71–73]. However, children exposed
to triptans in utero might have a higher risk of developing
externalizing behaviors [74]. Exposure to triptans in late
pregnancy is associated with an increased risk of atonic
uterus and postpartum haemorrhage [37, 56, 60, 61, 69, 72,
73, 75, 76]. In their meta-analysis, Marchenko et al. Con-
cluded that triptans do not lead to increased rates of major
congenital malformations [76]. The rates of spontaneous
abortions were elevated when compared to healthy controls
(OR 3.54), but not with untreated migraineurs [76]. Entries
in pregnancy registries are voluntary and therefore not
systematic. Most registers and observational studies do not
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include sufficient data about how often triptans were taken,
exposure to concomitant medications or severity of illness
as a possible confounders [76–78]. Some concern exists on
a potential increased risk of behavioral problems like atten-
tion deficit and aggression disorders after prenatal exposure
to triptans, in particular in the first trimester [74].
The use of sumatriptan is compatible with breastfeeding
without the need to “pump and dump”. The infant expos-
ure is very low corresponding to 0.5% of maternal dose
and no adverse events on the nursing infant were reported
[77]. Theoretically, eletriptan can be considered even safer
as the dose in breast milk is only 0.002% after 24 h [36].
Clear controlled evidence on the other triptans is lacking.
They are considered probably compatible with breastfeed-
ing [37, 57, 59, 61, 62, 64, 79]. As an extra safety measure
it can be advised to avoid breastfeeding for 24 h after their
use [59].
Oxygen
In pregnant and breastfeeding women with CH, high flow
oxygen administered via a non-rebreathing mask is the
preferred treatment. It seems a safe option without proven
adverse effect on the child or the mother [50, 57, 79, 80].
Lidocaine
The use of lidocaine is a considerable option for pregnant
women with CH, when treatment with oxygen is insuffi-
cient [50, 57, 80]. The intranasal formulation is preferred
since it is presumed to have a better safety profile than the
systemic formulations [80].
Lidocaine is compatible with breastfeeding in any
formulation [57, 64, 79, 80].
Corticosteroids
There is some concern about early lung maturation and
a slightly increased risk for cleft palate, but in disabilitating
CH and status migrainosus prednisone and prednisolone
remain a reasonable alternative [57, 60, 65, 80]. Therefore,
they should be avoided during first trimester and the dose
should be kept as low as possible [80].
Oral prednisone and prednisolone are compatible with
breastfeeding as only about 1–2% of the mother dose
transfers to the fetus [64]. Prolonged high-dosed therapy
should be avoided since infant growth and development
could be affected [57, 64]. When administered intraven-
ously, breastfeeding should be delayed untill 2 to 8 h
after administration [80].
Opioids
Weak opioids like tramadol and codeine can be con-
sidered when non-opioid medication brings no relief
[37, 61, 66, 81]. Codeine was initially supposed to in-
crease the risk for cleft palate and inguinal hernia but
large observational studies could not confirm it [81].
A slightly higher risk for cardiac defects or spina
bifida has been described after opioid exposure in first
trimester [61]. Prolonged use of such drugs should be
clearly discouraged because of the risk of medication
overuse headache (MOH) for the mother and dependency
with withdrawal syndrome in the newborn [37, 62]. Stron-
ger formulations should be used with caution and opioid
use is discouraged during third trimester, since narcotics
cross the placenta and can cause fetal bradycardia, respira-
tory depression and birth defects [61, 62].
Sporadic use of weak opioids is compatible with breast-
feeding. When repeated dosing or highly dosed opioids are
needed, there is a risk of sedation, respiratory depression
and constipation in the infant [37, 61, 64].
Ergots and ergots alkaloids
Ergots and ergots alkaloids are contraindicated in preg-
nancy due to a known uterotonic and vasoconstrictive
effect as well as a range of serious adverse effects on the
fetus like fetal distress and birth defects [18, 37, 50, 57,
59, 61, 62, 66]. Other possible teratogenic effects include
intestinal atresia and poor cerebral development [3].
They should be avoided in nursing women. Beside sys-
temic side effects in the infant like vomiting, diarrhea and
convulsions, prolactine can be decreased by these drugs,
reducing the milk production [37, 59, 61, 64].
Antiemetics
Antiemetics are believed to be mostly safe during preg-
nancy [21]. However, only little data are available.
Metoclopramide is commonly used during pregnancy
without significant fetal side effects [50, 54, 57, 59, 61, 62].
Chlorpromazine and prochlorperazine could have an in-
creased risk for neonatal extrapyramidal or withdrawal
symptoms if taken during third trimester [37], domperi-
don might lead to long QT syndrome [82], and under
diphenhydramin, sedation and apnea after delivery are
possible [64].
Doxylamine, histamine H1 receptor antagonists, pyri-
doxine, dicycloverine and phenothiazines are other op-
tions without noted adverse pregnancy outcomes [54].
Recently some concerns arised on the use of ondansetron
during pregnancy. There seems to be conflicting evidence
about a possible teratogenic effect as well as the potential
to cause a serotonin syndrome and QT prolongation [37].
A potential toxicity of metaclopramide, chlorpromazine
and prochlorperazine for the infant is suspected when
used in nursing mothers [57, 59, 64]. Antiemetics could
lead to sedation or irritability, but also apnea and extrapyr-
amidal symptoms are possible [37].
Based on the above mentioned informations paracetamol
500 mg alone or in combination with aspirin 100 mg,
metoclopramide 10 mg, or tramadol 50 mg are recom-
mended as first choice symptomatic treatment of a
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moderate-to-severe primary headache during pregrancy.
Sumatriptan may be the second choice symptomatic treat-
ment for migraine in pregnant women.
Preventative treatment
Antihypertensive drugs
Β-blockers (metoprolol and propranolol) are the first line
option as migraine prophylaxis in pregnant and breastfeed-
ing women. [37, 54, 59–61]. Potential fetal side effects like
intrauterine growth retardation, preterm birth and re-
spiratory distress are described in some studies [37, 60].
If possible a prelabour tapper off should be achieved as
the use of β-blockers in the third trimester can induce neo-
natal pharmacological effects like bradycardia, hypotension
and hypoglycaemia. Newborns exposed in the last trimester
should be closely monitored [37, 61].
Β-blockers are excreted in breast milk in very low doses
and infant plasma concentrations are negligible. When
nursing, metoprolol is preferred over propranolol. Possible
side effects include drowsiness, neonatal hypoglycemia,
hypotension, weakness and bradycardia [37]. Caution has
to be paid in infants with astma [64].
Antihypertensive drugs which interfere with the renine-
angiotensine system, like the ACE inhibitor lisinopril or the
angiotensin-receptor blocker candesartan, are considered
contraindicated at any stage of pregnancy since their use
involves a significant fetal risk [37, 61]. Candesartan is
probably compatible with breastfeeding with special atten-
tion for kidney development [64]. Lisinopril seems probably
compatible as well, but there is no specific breastfeeding
data available [64].
When prophylactic treatment is needed in a pregnant
or breastfeeding CH patient, verapamil in the lowest
effective dose remains the first choice [57, 64, 79, 80].
Antidepressants
The tricyclic antidepressants (TCA) are considered the
safest second-line option when β-blockers are contrain-
dicated or ineffective. Amitriptyline is preferred. Some
studies suggest a possible teratogenic effect of TCA (e.g.,
cardiovascular or limb abnormalities), but a clear causal
relationship can not be proven [18, 37, 59, 61, 62]. If
used late in pregnancy, all antidepressants might lead to
withdrawal symptoms [82]. Amitriptyline and nortripty-
line are relatively safe during breastfeeding. In mothers
treated with amitriptylin, infants are exposed to about
1–2% of maternal dose and no accumulation is supposed
[60] and this does not seem to have a negative impact
on the child [59–61, 64]. However, drowsiness and anti-
cholinergic symptoms like dry mouth or constipation
might occur [37].
The seretonin norepinephrine reuptake inhibitor (SNRI)
venlafaxine should be avoided during pregnancy. There is
no clear indication of a possible teratogenic or abortifacient
effect of duloxetine. No adverse pediatric effects have been
reported in the little data on nursing infants of mothers
using the snris duloxetine and venlafaxine [50, 60, 62, 64].
Antiepileptic drugs
Valproate is contraindicated during pregnancy because
of devastating fetal side-effects like neural tube defects
and other major malformations such as cleft palate, cardiac
or urinary tract defects [37, 54, 61, 83]. Valproate transfers
to breast milk in very low doses and is unlikely to affect the
child seriously [37]. Although valproate seems safe when
breastfeeding, it should be avoided in women of childbear-
ing age because of its teratogenic effect. When nursing on
valproate can not be avoided, monitoring for liver and
platelet function in the child is advised [59, 61, 64].
The use of topiramate in pregnancy is associated with
an increased risk of cleft lip/palate and low birth weight,
especially when taken during first trimester [81]. The
possible benefits as a migraine prevention do not seem
to outweigh the risks. Therefore topiramate should be
avoided in this context [37, 54, 60, 62, 84]. Topiramate
reaches infant plasma level up to 25% of maternal levels
and newborns should be monitored for sedation, irrit-
ability, poor suckling, weight loss and diarrhea. No other
significant side effects have been reported [61, 64, 84].
Data on prenatal exposure to gabapentin are limited.
A link with osteological deformities is suspected. Therefore,
its use is not recommended during pregnancy [54, 60].
Gabapentin seems compatible with breastfeeding. No
special concerns were reported to date [64].
Lamotrigine has a good safety profile compared with
other antiepileptic drugs, therefore, it is the preferred
option for women of child-bearing age. A recent meta-
analyses found that rates of miscarriages, stillbirths, pre-
term deliveries, and small for gestational age neonates
are not increased after in-utero exposure to lamotrigine
compared to the general population [85]. Similarly, in-
utero exposure to lamotrigine does not seem associated
with increased rates of inborn defects and long-term
neurodevelopmental damage [85].
The treatment with lamotrigine during breastfeeding is
safe and no serious adverse effects or cognitive and de-
velopment alterations have been reported [86].
Dietary supplements
Magnesium (up to 350 mg/die) can be used during preg-
nancy [81]. However, transient neurological symptoms
in newborns and hypotonia have been reported [82]. If
magnesium is administered intravenously over a long
time, bone abnormalities are possible [37]. Due to these
findings chronic use of magnesium during pregnancy
seems more controversial now than before [37, 62].
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Coenzyme Q10 seems a reasonable option for pre-
ventative treatment while pregnant. Up to date there are
no severe adverse events reported [37, 58].
Feverfew (Tanacetum parthenium), butterbur (Petasites
hybridus) and high dosed riboflavine are not recommended
during pregnancy [37, 61].
Both magnesium and riboflavine are compatible with
breastfeeding. About the safety of coenzyme Q10, fever-
few and butterbur in lactation no clear information is
available [61, 64].
Flunarizine
Calcium channel blockers should be avoided in pregnancy
and breastfeeding, since there are not enough safety
data [37, 54, 61].
Lithium
Lithium in CH should generally not be used in pregnancy
because of a known teratogenic effect. It is associated with
congenital cardiac malformations and cardiac arrhythmias,
anomalies of the central nervous sytem and endocrine sys-
tem, polyhydramnios and stillbirth. Use of lithium can be
considered in pregnant severe CH patients when verapamil
is ineffective, if the benefit to the mother clearly exceeds
the possible risk to the fetus [57, 62, 79, 80].
Lithium reaches a high relative infant dose of 50%.
Mainly the kindney in newborns seems sensitive to lithium
and renal toxicity is described [57].
Prescription of lithium in lactating women is contro-
versial but as in pregnant women, in cases of severe un-
controlled CH it can be considered [57, 79].
Botulinum toxin type a
Botulinum toxin type A is probably safe during preg-
nancy due to its local mechanisms of action. However,
only very few data are available and mainly for its use as
cosmetic treatment [61].
There are no reports for botulinum toxin type A dur-
ing breast-feeding but a transfer to breast milk is not
probable due to its high molecular weight [61].
As no well-controlled data is available for his indication
for now it should only be reserved for severe treatment-
refractory chronic migraine patients [37, 61, 87].
Nerve blocks
Periferal nerve blocks are considered safe in pregnancy
and breastfeeding. Due to their periferal localization, the
systemic effect is considerably smaller than in oral medi-
cation. The preferred agent to inject is lidocaine. Alterna-
tives are bupivacaine or betamethasone. Bupivacaine may
be associated with fetal cardiotoxicity [37, 57, 62, 88, 89].
Melatonin
There is no clear evidence of harmfull adverse events
when using melatonin during pregnancy. However it is
suggested that administration of exogenous melatonin
during pregnancy can interfere with the development of
the postnatal circadian rhythm [79].
Melatonin is a natural substance of breastmilk and is
excreted in a circadian cycle. Hypotheticaly the use of
exogenous melatonin can be thought to have a negative
influence on postnatal sleep patterns and other hormo-
nal cycles. There is no relevant data available to support
this hypothesis [79]. Melatonin in low doses seems com-
patible with breastfeeding [64].
Headache-related complications during
pregnancy
Headache during pregnancy requires particular attention
because it can be a symptom of secondary conditions,
including CVT, hypertensive disorders, stroke and pituit-
ary apoplexy [50]. At the same time, preexisting primary
headache conditions can influence the course of preg-
nancy and delivery, and lead to a higher risk of compli-
cations [18].
Pregnancy complication in migraine patients
Most previous literature focused on the effects of mi-
graine on pregnancy, while other headache disorders
were often neglected. In general, a preexisting migraine
does not represent a risk factor for negative pregnancy
outcome and no increase rate of fetal malformations
could be detected in pregnant women suffering from
migraine [3, 41]. However, migraine can be considered
an important risk factor for hypertensive and vascular
diseases during pregnancy [90].
The largest study to investigate the relationship between
migraine and pregnancy complications was conducted by
Bushnell et al. In form of a retrospective, population based
case-control study on 18,345,538 pregnancies in the United
States between 2000 and 2003 [91]. 33,956 (0.2%) of the
examined pregnant women had a migraine diagnosis. The
authors detected a strong correlation between migraine and
vascular diseases. In particular, the risk for stroke was 15-
fold higher, with odds ratios of 30.7 for ischemic and 9.1 for
hemorrhagic stroke. Other vascular conditions at elevated
risk were myocardial infarction and other heart diseases
(OR 2.1), thromboembolic conditions (OR 3.2), hyperten-
sion (OR 8.6), pregnancy-hypertension and preeclampsia
(OR 2.3) [91].
Banhidy et al. Conducted a similar study analyzing
retrospectively data from the Hungarian Case-Control
System of Congenital Abnormalities between 1980 and
1996 [92]. They collected data from 38,151 infants, 713
(1.9%) of them were born from mothers with a migraine
diagnosis. The risk of congenital malformations was not
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increased but migraine was associated with a 1.4-fold
higher risk of preeclampsia [92]. Also Chen et al. Detected
in a retrospective study on 4911 Taiwanese women with
migraine an elevated risk for preeclampsia (OR 1.3), when
compared to 24,555 women without migraine. Moreover,
they detected an elevated risk for preterm birth (OR 1.24)
and low birth weight (OR 1.2) [93].
Comparable results regarding elevated risk for pre-
eclampsia were collected by Simbar et al. In a retrospect-
ive study on 180 Iranian pregnant women; those with a
history of migraine had a 2.7-fold higher risk for develop-
ing preeclampsia [94].
In one prospective study, Facchinetti et al. Examined
the data of 702 pregnant women who were normotensive
before pregnancy; the 38.5% of them reporting migraine
headache had a 2.8-fold higher risk of developing hyper-
tensive disorders during pregnancy [95]. This risk was par-
ticularly elevated for women with active migraine during
pregnancy and remained significant even after adjusting
for other common risk factors for hypertension such as
age, smoking and positive family history. Women with
migraine were also at a 1.9-fold higher risk for giving birth
to low birth weight infants [95].
Similar results were reported in a more recent, smaller
study by Grossman et al. [96]. They analyzed retrospect-
ively the data of 86 pregnant women with migraine, who
gave birth between 2009 and 2014. Their cohort con-
sisted mostly of African-American and Hispanic women.
In comparison with national averages, patients experien-
cing severe migraine attacks during pregnancy had a
higher rate of complications during pregnancy and deliv-
ery, including preeclampsia (21.3% vs. 4%), preterm de-
livery (28.0% vs. 11.4%) and low birth weight (18.7% vs.
8%) [96]. Moreover, if migraine patients develop pre-
eclampsia, they have also an increased risk for cerebral
palsy and perinatal death [97].
The relationship between migraine and other vascular
conditions remains unclear and is most probable related
to overlapping pathophysiological mechanisms [21]. In
the mentioned studies, the authors discuss possible common
etiological backgrounds, including platelet hyperaggregation,
decreased prostacyclin production, altered vasoreactivity and
endothelial dysfunction [3, 98]. Supposedly, women with
migraine have poor vascular compensation mechanisms in
stress situations like pregnancy, leading in return to a higher
incidence of vascular complications [91].
The risk of developing hypertensive disorders appears
particularly high if other comorbidities are present.
Czerwinski et al. Detected a 2.5-fold higher risk of devel-
oping pregnancy-induced hypertension in patients
with migraine and additionally asthma [99]. Also co-
morbid mood-disorders can increase the risk of pre-
term birth and hypertensive disorders in pregnant
migraineurs [100].
Furthermore, migraine is associated with a higher risk
of nausea and hyperemesis gravidarum [92, 101]. Pregnant
migraineurs complain significantly more often about short
sleep duration, excessive daytime sleepiness, vital exhaus-
tion and elevated perceived stress [102, 103].
Patients with migraine also have an elevated risk for
depression during pregnancy and increased rates of
anxiety and stress, especially in cases of migraine with
aura [100, 103]. Some authors suggest that migraine
and depression may share a common pathophysiology
with dysfunction in the serotonergic and dopaminergic
system [100].
Pregnancy complications in patients with other headache
conditions
Only few studies included pregnant patients with other
primary headache conditions than migraine. Maggioni
et al. Conducted a retrospective study on 430 women
after delivery: 126 (29.3%) suffered from primary head-
ache disorders, among them 81 had MO, 12 MA and 22
TTH [5]. They detected no differences in APGAR scores
(a method to quickly summarize the health of newborn
children) and malformations between women with and
without primary headaches, regardless of the headache
subtype [5].
Sanchez et al. Observed that history of headache cor-
related significantly with placental abruption, i.e. The
separation of the placenta from uterus before delivery
[104]. The odds ratio for MA was 1.59, for MO was 2.11
and for TTH was 1.61 [104].
Finally, Marozio et al. Conducted a prospective study
on 376 pregnant women with headache compared to
326 pregnant women without headache [105]. Among
women with headache, 264 had migraine with or with-
out aura and 103 a TTH. Preterm deliveries occurred
significantly more often within the headache group and
headache subtypes did not differ regarding pregnancy
complications [105].
In conclusion, migraine is a risk factor for pregnancy
complications, particularly vascular events [39, 97]. The
risk of gestational hypertension and preeclampsia is in-
creased in pregnant migraineurs and active migraine
during pregnancy is associated with increased risk for
stroke, cardiac diseases and thromboembolic events [39].
Therefore, migraineurs should be considered at higher
risk for complications during pregnancy and monitored
closely [39].
Data regarding other primary headache conditions are
scarce. Although some authors suggested a higher risk
for pregnancy complications in all headache patients
regardless of the subtype, further research is needed to
validate these results and examine possible common
etiological factors [105].
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Diagnostics of headache in pregnancy
Headache during pregnancy can be both primary and
secondary, and in the last case can be a symptom of a
life-threatening condition. During pregnancy, migraine
and TTH are most common, however, there may occur
conditions that resemble primary headaches but are
symptoms of disorders first appearing during pregnancy.
Early diagnostics of the disease manifested by headache
is important for mother and fetus life.
For a differential diagnostics of headaches is important
to collect the anamnesis: it is necessary to investigate
family aptitude to headache, the age of its debut, whether it
is a new or emerging condition; it is also important get a
detailed description of its episode and its accompanying
symptoms. The presence of headache before pregnancy is
an important predictor of its development during or after
pregnancy. It is also important to find out possible associ-
ated diseases that could trigger or worsen the course of
headache. In addition, it is mandatory to consider adminis-
tered medications. If there is a suspicion of the symptom-
atic character of the headache, it is necessary to carry out a
neuroimaging, lumbar puncture and other methods [38].
Primary headaches during pregnancy
When MA occurs for the first time during pregnancy, it
is necessary to conduct brain MRI to prevent ischemic
stroke. Generally, migraine does not affect the outcome
of pregnancy, but it is more likely to experience premature
birth and preeclampsia [25, 106].
In addition to migraine during pregnancy, TTH is also
quite common. The nature of pain, its localization, dur-
ation, as well as the conditions under which pain occurs,
worsens and weakens play role in its diagnostics. In case
of prolonged headache not improved by analgesics, it is
advisable to perform ophthalmoscopy and brain MRI to
exclude volume formations and intracranial hypertension.
Cluster headache is a relatively rare type of headache.
Its extensiveness is approximately 0.06% of the population,
with a total ratio of men to women of approximately 2.5:1
[57]. To exclude the secondary nature of the headache, it
is also advisable to perform brain MRI.
Secondary headaches during pregnancy
It is especially important to identify “red flags” suggesting
that headache is a symptom of a serious disease (Table 2).
In these cases, electroencephalography, ophthalmoscopy,
ultrasound of the vessels of the head and neck, brain MRI
and MR angiography may be needed [38]. In some cases,
it is possible to perform multi-slice computed tomography
(MSCT). The risk for the fetus in this case is minimal and
the contraindication is the mother allergy to the contrast
agent [107].
Clinically, the most significant causes of the secondary
headache in pregnant women are: stroke, subarachnoid
hemorrhage, cerebral venous thrombosis, arterial dissec-
tion, pituitary tumor, choriocarcinoma, eclampsia, pre-
eclampsia, posterior reversible encephalopathy syndrome,
idiopathic intracranial hypertension, and reversible cere-
bral vasoconstriction syndrome.
Stroke (acute cerebrovascular accident)
To identify the etiology and make a diagnosis of ACA in
pregnant women and puerperas, one or more of the fol-
lowing methods can be required: MRI and angiography,
computed tomography (CT), MSCT, ophthalmoscopy
electrocardiography and echocardiography, daily monitor-
ing of arterial pressure and electrocardiograms, ultrasound
examination of extra- and intracranial vessels with duplex
scanning, and cerebral angiography [108].
Subarachnoid hemorrhage
Subarachnoid hemorrhage is caused by rupture of aneurysm
or vascular malformations (arteriovenous malforma-
tion, cavernous or venous hemangioma). Intracerebral
hemorrhages in pregnant women are rare. The risk of
SAH is especially high in the first few days after birth.
Diagnosis is confirmed by non-contrast-enhanced CT
scan, which has a sensitivity of 98% in the first 12 h
after onset [42]. If CT results are non-diagnostic, a lumbar
puncture is essential. MRI is not indicated as an initial
diagnostic test for SAH but may be useful when the CT is
normal and the CSF abnormal [42]. Also, cerebral angiog-
raphy can be performed, which allows determining the
number of aneurysms and arteriovenous malformations,
as well as their localization [108].
Cerebral venous thrombosis
CVT is a serious secondary headache disorder that can
occur with pregnancy, usually during the 3rd trimester
and postpartum period. Given the absence of specific
characteristics, any recent persisting headache should
raise suspicion, particularly in the presence of risk factors
for CVT, such as hypertension, prothrombotic conditions,
cesarean delivery, advanced maternal age, infections, and
excessive vomiting. The rate of death with CVT is 2–10%,
but less when associated with pregnancy [109]. Diagnosis
is based on neuroimaging: MRI plus MRA, or CT scan
plus CT angiography, and intra-arterial angiography in
doubtful cases.
Arterial dissection
Headache associated to arterial dissections has no con-
stant specific pattern and it can sometimes be very mis-
leading, mimicking other headaches such as migraine, CH
or primary thunderclap headache [42]. A painful Horner’s
syndrome, painful tinnitus of sudden onset or painful xiith
nerve palsy are highly suggestive of carotid artery dissec-
tion. Cervical artery dissection may be associated with
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intracranial artery dissection, which is a potential
cause of or intracranial haemorrhages (subarachnoid
or intracerebral).
Headache attributed to cervical arterial dissection usually
precedes the onset of ischaemic signs, and therefore re-
quires early diagnosis and treatment. Diagnosis is based on
cervical MRI, Duplex scanning, MRA and/or CTA and, in
doubtful cases, conventional angiography [42]. Several of
these investigations are usually needed as any of them can
be normal.
Pituitary tumor
Pituitary tumors account for 10% to 22% of all neo-
plasms of the brain. One of the most common pituitary
tumors is prolactinoma. In most cases, the pathology
proceeds without any apparent symptoms. Visual disturb-
ance and headaches occur only when the size of the tumor
increases and is more than one centimeter. During preg-
nancy it is occurs rarely.
Microadenoma and pregnancy are poorly compatible
with each other. In many cases, spontaneous abortion
occurs in the first trimester. The most severe complica-
tion of the increase in size of a pituitary adenoma is
apoplexy, resulting from hemorrhage or infarction of the
tumor, which is usually accompanied by acute headache,
visual impairment and pituitary dysfunction [110].
A pregnant woman with prolactinoma must be exam-
ined every 3 months and it is necessary to find out the
presence of symptoms of tumor growth: headache, visual
field disturbances, and abnormalities at the ophthalmos-
copy [111]. MRI is performed only with the appearance
of clinical symptoms indicating a tumor growth [112].
Choriocarcinoma
In Europe and North America, choriocarcinoma affects
approximately 1 in 40,000 pregnancies [113]. A delay in
diagnosis may lead to metastatic organ damage. When
metastasizing in the central nervous system, there is
headache, intense dizziness, darkening in the eyes, or
other symptoms of volume formation in the brain. For
diagnosis, brain MRI or CT scan can be sufficient and, if
they result negative, a lumbar puncture can be performed.
The determination of the concentration of chorionic
gonadotropin (HCG) in the cerebrospinal fluid (CSF) and
blood allows detecting initial metastases. HCG poorly
penetrates the blood-brain barrier. A ratio of HCG con-
centration in the blood and in CSF less than 40:1 indicates
the involvement of the CNS [114].
Headache associated with preeclampsia and eclampsia
Headaches are noted in 2/3 of all patients with preeclampsia
or eclampsia [115, 116]. Preeclampsia is a preconvulsive
condition characterized by a significant rise in blood
pressure, a high protein concentration in the urine, and
significant edemas. It occurs after the 20th week of
pregnancy or in the postpartum period. Eclampsia is a
convulsive seizure, which is preceded by a headache
and a flash of light feeling. This state is either allowed
or goes into a coma. Risk factors for the development
of preeclampsia and eclampsia are overweight, hyperten-
sion, age over 40, diabetes, kidney disease, and multiple
pregnancies. The occurring of preeclampsia increases the
risk of hemorrhagic stroke developing during pregnancy
and childbirth [117]. In addition, it is important to know
that eclampsia is the most common cause of death of preg-
nant women [87, 118]. In women with eclampsia, seizures
are preceded by headache similar to migraine, with pulsat-
ing character, different localization, accompanied by nausea
or vomiting, photophobia and phonophobia [92]. The de-
layed postpartum eclampsia may occur within 1 week after
childbirth, and its most common symptom is headache
[119]. Each pregnant woman after 20 weeks of pregnancy
suffering from a difficult-to-maintain headache should be
examined for preeclampsia [120–124]. Diagnostic criteria
for headache associated with preeclampsia and eclampsia
are presented in the ICHD-3beta [42].
Posterior reversible encephalopathy syndrome
The clinical symptoms are usually non-specific and the
differential diagnosis of PRES in pregnancy and puerperium
may be challenging. The presentation can be mistaken
for other conditions such as eclampsia, ischaemic and
haemorrhagic stroke, CVT, RCVS, cerebral artery dissec-
tion, metabolic and demyelinating disorders, vasculitis and
encephalitis [125]. CT imaging in PRES show lesions in
only about 50% [126]. MRI represents the gold standard
for this condition and leads to the correct diagnosis in
most cases and may, therefore, forestall further investiga-
tions. Typical findings are bilateral and symmetrical white
matter vasogenic oedema in the parieto-occipital regions;
however, lesions can occur in both white and grey matter
and can involve the frontal and temporal lobes, basal
ganglia, brain stem and cerebellum [127].
Primary and secondary intracranial hypertension
The symptoms of idiopathic intracranial hypertension
(IIH) are daily progressive non-pulsating headaches,
which increase with the change in the body position and
also with the Valsalva probe, with a transient feeling of
darkening in the eyes and pulsating noise in the ears
[121, 128, 129]. Most often IIH occurs in women of
childbearing who are overweight. For the diagnosis is
necessary to determine the absence of the brain substance
defects and signs of thrombosis of the brain sinuses, there-
fore it is necessary to carry out brain MRI and MR angiog-
raphy. In addition, it is necessary to define the absence of
high pressure of CSF and changes in its composition. An
important diagnostic sign is edema of the optic nerve disk
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and progressive diplopia, which in the absence of adequate
therapy, can be irreversible [121]. However, in one out ten
cases otpic disk edema may be absent in IIH, since it takes
weeks or months to develop [130].
The causes of secondary intracranial hypertension (SIH)
may be different, including volume intracranial formations.
More than the half of cases depends on venous sinuses
thrombosis. The most frequent variant are thrombosis of
cortical veins, causing headaches together with focal epilep-
tic attacks, and thrombosis of the veins of the dura mater,
resulting in a series of headaches, focal epileptic seizures
and focal neurological deficiency. Cerebral vein thrombosis
can occur during any gestation age, but more often in the
postpartum period. MRI and MSCT venography are the
most informative methods for detecting thrombosis of
intracranial veins and sinuses [131].
Reversible cerebral vasoconstriction syndrome
Reversible cerebral vasoconstriction syndrome was con-
sidered a very rare disease in pregnant women, but over
the time this condition became diagnosed more often,
as postpartum angiography became possible to conduct
[123]. The main symptom is “thunder-like headache” at
the beginning of the disease with angiographic signs of
vasoconstriction. The principal risk factor is a high
concentration of vasoconstrictor substances in the body
of a pregnant woman. This syndrome can also develop
in the postpartum period due to the use of ergometrine
maleate in postpartum hemorrhage [124]. The diagnostic
criteria for headaches associated with reversible cere-
bral vasoconstriction syndrome are presented in ICHD-
3beta [42].
Postpartum headache
In the postpartum period, the frequency of headache in-
creases, mostly depending on the return of migraine, but
also as a result of epidural anesthesia [120]. Headache
that appeared after epidural anesthesia is quite typical. It
is caused by a decrease in CSF pressure, occurs unexpect-
edly 1 to 7 days after puncture and has a positional charac-
ter. Differential diagnosis of secondary headache in the
postpartum period is carried out for postpartum eclampsia
and subdural hematoma [121], angiopathy [132, 133], men-
ingitis, cerebral thrombosis of veins and sinuses [120, 134],
stroke, pituitary tumor, and chorioocarcinoma.
Conclusions
Headache is a common complaint in the general popula-
tion, particularly in females. Therefore, it is not surprising
that it is a frequent presentation in pregnant women. Pri-
mary headaches, such as migraine and tension headache,
account for most headaches in pregnancy. Most women
notice their headache either go away or greatly improve in
the second and third trimesters of pregnancy, possibly due
to a reduction in reproductive hormonal fluctuation.
However, around 10% experience a worsening of symp-
toms and after delivery, most women quickly return to
their pre-pregnancy migraine pattern.
Pregnancy creates alterations in maternal physiology
that increase the risk of several dangerous secondary
headache disorders, especially those associated with vascular
endothelial dysfunction and hypertensive disorders of preg-
nancy. It is fundamental to consider secondary causes in the
differential diagnosis of headache, which may require urgent
investigation. Pre-eclampsia, eclampsia, CVT, certain types
of ischemic and hemorrhagic stroke, SAH, pituitary apo-
plexy, RCVS, PRES, and thunderclap headache show an
overlapping clinical presentations and need to be treated
emergently. One or more between electroencephalography,
ultrasound of the vessels of the head and neck, brain MRI
and MR angiography with contrast, brain CT, ophthalmos-
copy and lumbar puncture will distinguish primary and
secondary headaches.
Pregnancy and lactation can complicate treatment
options for women with migraine because of the risk of
certain medications to the fetus and because medications
are passed on in a mother’s milk to varying degrees.
Paracetamol use in pregnancy is safe and ibuprofen
can be prescribed for short-term use in the first and second
trimesters. There are increasing safety data on triptans to
treat migraine in pregnancy and, if other treatments have
failed, sumatriptan may be used to treat acute migraine
attacks also while nursing.
Options in prescription preventive medications are lim-
ited and it may be best to consider the safest interventions,
which are lifestyle changes and behavioural treatment for
stress management. When preventive pharmaceutical treat-
ment is needed for migraine metoprolol and propranolol
are the first choice followed by amitriptyline. Little data are
available for Botulinum toxin type A use.
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